SCHEMBL7535753

SCHEMBL7535753

COc1ccc(NS(=O)(=O)c2c(F)c(F)c(OC(=O)C(F)(F)F)c(F)c2F)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
HTT P42858 3/20 0.44
ALDH1A1 P00352 3/20 0.44
THRB P10828 2/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 2/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FABP4 P15090 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40
HPGD P15428 1/20 0.40
HTR6 P50406 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7541533 0.90 L3MBTL1 (0.41) LMNAMEN1KMT2AHTTALDH1A1
SCHEMBL28762050 0.85 LMNA (0.51) LMNAMEN1KMT2AHTTALDH1A1
SCHEMBL6681134 0.85 MEN1 (0.46) LMNAMEN1KMT2AHTTALDH1A1
Batabulin SCHEMBL18845 0.84 LMNA (0.54) LMNAMEN1KMT2AHTTALDH1A1
Batabulin SCHEMBL29373304 0.84 LMNA (0.54) LMNAMEN1KMT2AHTTALDH1A1
SCHEMBL7533381 0.83 ALDH1A1 (0.48) LMNAALDH1A1SMN1; SMN2MAPK1HPGD
Batabulin SCHEMBL6086887 0.83 LMNA (0.53) LMNAMEN1KMT2AHTTALDH1A1
Batabulin SCHEMBL6089508 0.83 LMNA (0.53) LMNAMEN1KMT2AHTTALDH1A1
SCHEMBL28762112 0.82 LMNA (0.44) LMNAMEN1KMT2AHTTALDH1A1
SCHEMBL28762062 0.82 LMNA (0.44) LMNAMEN1KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 LMNA 2006/4885MEN1 2231/4885KMT2A 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.